Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 8

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 8
---
 of Directors when a series of preferred
stock is designated.

ATM
Agreement

On
February 14, 2025, the Company filed a shelf registration statement with the SEC to facilitate the issuance of our common stock and entered
into an At The Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC under which the Company may offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000.
As of March 31, 2025, the Company has not sold any shares under the ATM Agreement. (See Note 8.)

Warrants

In
connection with various transactions and the IPO summarized below, the Company issued stock warrants. Warrant activity for the three
months ended March 31, 2025 and 2024 is summarized below:

Schedule
of warrant activity

    Weighted  

    Weighted  
    Average  

    Number
    of  
    Average
    Exercise  
    Remaining
    Contractual  
    Aggregate
                                                                  Intrinsic 

    Warrants  
    Price  
    Term
    (Years)  
     Value 
  
    Outstanding
    as December 31, 2023 
     2,774,057  
    $4.85  
     4.5(1) 
        - 
  
    Granted 
     50,000  
    $7.0  
     4.1  
     - 
  
    Outstanding as
    March 31, 2024 
     2,824,057  
    $4.89  
     4.49  
     - 

    Outstanding as
    December 31, 2024 
     2,814,057  
    $4.97  
     3.49(2) 
     - 
  
    Granted 
     -  
    $-  
     -  
     - 
  
    Outstanding as
    March 31, 2025 
     2,814,057  
    $4.97  
     3.2(2) 
     - 
  
    Exercisable, March 31,
    2025 
     2,814,057  
    $4.97  
     3.2(2) 
     -